B-OM's potential competitor, AG013 released positi
Post# of 72435
![Avatar](/images/ProfileImages/398685088_3064_306524.png)
Oragenics enrolled just 24 out of 200 patients for their Phase 2 trial so they are way behind B-OM.
"We expect to report top-line results of the completed phase 2 trial in late 2019."
https://www.oragenics.com/news-media/press-re...is-results
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)